January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading
LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type
New Phase 1 POINT-HD study starts for selective huntingtin-lowering approach Dear Huntington’s community leaders, Following your request to receive updates about our research efforts, we are pleased to share that
One of the hardest parts of living with Huntington’s disease isn’t the symptoms themselves, it’s navigating the medical system. From rushed appointments to misunderstanding symptoms, to being doubted or dismissed
Warsaw, November 19th, 2025. Dear members, As you might know, yesterday the European Huntington’s Disease Network (EHDN) developed a seminar about the topline results of uniQure, a pharmaceutical company that
There are mornings when I wake up and my body feels like a stranger. Some days, the movements are gentle, barely a whisper under the surface. Other days, they arrive
November 3, 2025 Dear Huntington’s Disease Community, We issued a press release today announcing that uniQure received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics
ADORE-DH was a Phase II trial of a potential stem cell therapy for HD. Sponsored by AZIDUS Brasil (a full-service clinical research organization), this randomized, double-blind, placebo-controlled study aimed to
Before I speak about Huntington’s disease, there’s often a pause in my chest. It’s not just the facts I’m weighing it’s the fear of how they’ll land. Will the listener’s
September 24, 2025 PDF Version ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity
January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading
LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type
New Phase 1 POINT-HD study starts for selective huntingtin-lowering approach Dear Huntington’s community leaders, Following your request to receive updates about our research efforts, we are pleased to share that
One of the hardest parts of living with Huntington’s disease isn’t the symptoms themselves, it’s navigating the medical system. From rushed appointments to misunderstanding symptoms, to being doubted or dismissed
Warsaw, November 19th, 2025. Dear members, As you might know, yesterday the European Huntington’s Disease Network (EHDN) developed a seminar about the topline results of uniQure, a pharmaceutical company that
There are mornings when I wake up and my body feels like a stranger. Some days, the movements are gentle, barely a whisper under the surface. Other days, they arrive
November 3, 2025 Dear Huntington’s Disease Community, We issued a press release today announcing that uniQure received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics
ADORE-DH was a Phase II trial of a potential stem cell therapy for HD. Sponsored by AZIDUS Brasil (a full-service clinical research organization), this randomized, double-blind, placebo-controlled study aimed to
Before I speak about Huntington’s disease, there’s often a pause in my chest. It’s not just the facts I’m weighing it’s the fear of how they’ll land. Will the listener’s
September 24, 2025 PDF Version ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity
English English 
Arabic
Bulgarian
Chinese
Czech
Danish
Dutch
Estonian
Finnish
French
German
Greek
Hungarian
Indonesian
Italian
Japanese
Latvian
Lithuanian
Polish
Portuguese
Romanian
Russian
Slovak
Slovenian
Spanish
Swedish
Turkish
Ukrainian
